<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Phosphorylase b kinase deficiency
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Phosphorylase b kinase deficiency
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Phosphorylase b kinase deficiency
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Basil T Darras, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William J Craigen, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sihoun Hahn, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (
         <a class="graphic graphic_figure graphicRef81164" href="/z/d/graphic/81164.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (
         <a class="graphic graphic_table graphicRef54417" href="/z/d/graphic/54417.html" rel="external">
          table 1
         </a>
         ). The age of onset varies from in utero to adulthood.
        </p>
        <p>
         Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See
         <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">
          "Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glycogen serves as the primary source of energy for high-intensity muscle activity by providing substrates for the generation of adenosine triphosphate (ATP). The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.
        </p>
        <p>
        </p>
        <p>
         This topic will review phosphorylase b kinase (PBK) deficiency (MIM #306000), which is usually an X-linked disorder. There is confusion over the GSD classification of PBK deficiency as both numbers VIII and IX have been assigned. An overview of GSD is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2941.html" rel="external">
          "Overview of inherited disorders of glucose and glycogen metabolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHOSPHORYLASE B KINASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         PBK is required for the activation of phosphorylase by converting the less enzymatically active phosphorylase b to the more active phosphorylase with a resulting increase in glycogenolysis. PBK also catalyzes the conversion of glycogen synthase from a more to a less active form. Because of these reciprocal changes, glycogen degradation is active when glycogen synthesis is inactive and vice versa.
        </p>
        <p>
         The enzyme is composed of four separate subunits (alpha, beta, gamma, delta), each encoded by a distinct gene [
         <a href="#rid1">
          1,2
         </a>
         ]. The holoenzyme is made up of four copies of each isoform for a final complex of 16 subunits.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         PBK (or PHK) deficiency is genetically heterogeneous, with both autosomal recessive and X-linked forms. This has led to inconsistent classification schemes. The disease has been subclassified depending on the subunit involved. Defects in the alpha subunit account for 75 percent of cases.
        </p>
        <p>
         PBK deficiency has considerable locus and allelic heterogeneity. The majority of cases are the X-linked liver-specific disease, caused by a variety of mutations in the phosphorylase kinase regulatory subunit alpha 2 (
         <em>
          PHKA2
         </em>
         ) locus at Xp22 and resulting in a defective alpha or L (liver isoform) subunit. A common cause of hepatic PBK deficiency in Dutch patients is a missense variant in the
         <em>
          PHKA2
         </em>
         gene that results in a leucine rather than a proline at amino acid 1205 (p.Pro1205Leu) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The mutation type in patients with disease isolated to the liver appears to correlate with clinical severity. Red blood cell enzyme activity is preserved with hypomorphic variants and lost with more severe loss-of-function variants [
         <a href="#rid4">
          4
         </a>
         ]. Rarely, female carriers of the X-linked form manifest clinical features.
        </p>
        <p>
         Mutations in the beta subunit of the phosphorylase b kinase gene (
         <em>
          PHKB
         </em>
         ) located at 16q12 have been described in patients with combined liver and muscle deficiency (glycogen storage disease [GSD] IXb) [
         <a href="#rid5">
          5,6
         </a>
         ]. Autosomal liver disease is caused by pathogenic variants in the catalytic gamma subunit encoded by the
         <em>
          PHKG2
         </em>
         gene at 16p12 (GSDIXc) [
         <a href="#rid7">
          7,8
         </a>
         ]. These patients risk a more severe fibrotic liver disease and hepatocellular carcinoma [
         <a href="#rid9">
          9
         </a>
         ], in addition to symptoms of hypoglycemia. Muscle-specific disease (GSDIXd) is caused by pathogenic variants in the muscle-specific alpha(M) subunit (
         <em>
          PHKA1
         </em>
         ) located at Xq13 [
         <a href="#rid6">
          6,10,11
         </a>
         ]. At least six patients have been described, generally with modest elevation of blood creatine phosphokinase (CPK) and variable degrees of exercise intolerance. One patient had cognitive impairment but no evidence of myopathy, and it was suggested that there is a central nervous system function for this subunit, which is known to be expressed in the brain [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         No pathogenic variants in the genes encoding the muscle-specific gamma (
         <em>
          PHKG1
         </em>
         ) and delta (
         <em>
          PHKD
         </em>
         ; also called calmodulin 1 [
         <em>
          CALM1
         </em>
         ]) PBK subunits have been described in myopathic patients with PBK deficiency.
         <em>
          CALM1
         </em>
         pathogenic variants have been reported in individuals experiencing catecholaminergic polymorphic ventricular tachycardia (CPVT), sudden death, and long QT syndrome [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of PBK (or PHK) deficiency are mild. They typically present in early childhood with growth retardation and hepatomegaly, sometimes with hypoglycemia or rarely hypotonia and developmental delay [
         <a href="#rid16">
          16
         </a>
         ]. Unlike some other glycogen storage diseases (GSDs) affecting the liver, the response to glucagon is normal.
        </p>
        <p>
         In a longitudinal study of 41 patients with PBK deficiency, the following features were described [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly – 92 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Growth retardation – 68 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delayed motor development – 52 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypercholesterolemia – 76 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertriglyceridemia – 70 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevated glutamate pyruvate transaminase – 56 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fasting hyperketosis – 44 percent
        </p>
        <p>
        </p>
        <p>
         The course generally is benign. Symptoms resolve over time so that most adults are asymptomatic. The initial growth retardation is typically followed by a spurt of growth that results in a final height that is normal [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Other presentations of PBK deficiency include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myopathy, which presents primarily with exercise intolerance, cramps, myalgias, weakness in exercising muscles, and, in rare cases, hypotonia in young children. Intense exercise-induced myoglobinuria has been reported in less than 50 percent of cases, usually in children or adolescents [
         <a href="#rid19">
          19
         </a>
         ]. In older individuals, progressive distal weakness is more prominent than proximal weakness [
         <a href="#rid11">
          11,20-23
         </a>
         ]. This myopathic form has autosomal or X-linked inheritance (see
         <a class="local">
          'Genetics'
         </a>
         above). Approximately 20 patients with pathogenic variants in the X-linked
         <em>
          PHKA1
         </em>
         gene for the alpha subunit of PBK have been reported thus far, and all presented with myopathic symptoms. However, a 17-year-old patient with a
         <em>
          PHKA1
         </em>
         gene variant not previously reported presented with cognitive impairment ("borderline" intellectual disability) but no signs of overt myopathy [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatal infantile cardiomyopathy was described in patients reported to have infantile-onset PBK deficiency [
         <a href="#rid24">
          24,25
         </a>
         ], a puzzling finding given that there is no cardiac isoform of PBK. However, it has since been determined that the "pseudo PHK deficiency" in these patients is secondary to de novo heterozygous activating pathogenic variants in the gamma-2 subunit of adenosine monophosphate (AMP) activated protein kinase (
         <em>
          PRKAG2
         </em>
         ) gene, the product of which is abundantly expressed in the heart [
         <a href="#rid26">
          26,27
         </a>
         ]. Adults with unclassified muscle glycogenosis and cardiac involvement with conduction abnormalities may harbor similar point mutations [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4956.html" rel="external">
          "Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing", section on 'PRKAG2 and LAMP2 genes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The liver and muscle disease subtype is characterized by liver enlargement and nonprogressive muscle disease in childhood [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical severity varies widely in patients with mutations in the gamma subunit of PBK gene (
         <em>
          PHKG2
         </em>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. Some patients may develop cirrhosis [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal onset has been described in a premature female newborn with history of diminished fetal movements, hypotonia at birth, absent spontaneous movements, increased flexor tone in the extremities, lack of psychomotor development, and death at two months due to central apnea [
         <a href="#rid32">
          32
         </a>
         ]. No hypoglycemic episodes were documented, and myocardial function was normal. While muscle biopsy and enzymatic studies were consistent with PBK deficiency, molecular confirmation of the diagnosis is missing in this case.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         To avoid tissue biopsies, deoxyribonucleic acid (DNA) testing can be performed first [
         <a href="#rid33">
          33
         </a>
         ]. If necessary, the diagnosis can be confirmed by reduced or absent PBK (or PHK) activity in the affected tissue, either liver or muscle. Patients with muscle involvement typically have elevated serum creatine kinase activity. If the liver is affected, biopsy reveals excessive glycogen accumulation. The rosettes have a less compact appearance than in other liver glycogenoses. Hepatic fibrosis may be seen.
        </p>
        <p class="headingAnchor" id="H755945993">
         <span class="h2">
          Molecular testing
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of next-generation sequencing panels is recommended because multiple genes are involved.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limitations of molecular testing should be recognized, and the diagnosis pursued by other methods if there is a strong clinical suspicion and molecular testing is negative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PBK (or PHK) enzyme activity can be normal or elevated in blood cells, including erythrocytes, in affected persons. Liver or muscle biopsy may be necessary for confirmation of the diagnosis if variants of unknown significance are identified by genetic testing [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Forearm ischemic exercise test
         </span>
         <span class="headingEndMark">
          —
         </span>
         In affected individuals, the forearm ischemic exercise test (FIET) reveals a normal or only partially impaired rise of venous lactate levels. This finding is probably related to activation of residual PBK by calcium or cyclic adenosine monophosphate (cAMP) dependent protein kinase or the direct activation of PBK by exercise-increased inosine monophosphate or inorganic phosphorous metabolites. In an adult patient with X-linked PBK deficiency, there was a normal lactate response during FIET. However, during 60 percent of maximal exercise, there was no increase in blood lactate compared with a fourfold increase in healthy controls [
         <a href="#rid35">
          35
         </a>
         ]. The different response of lactate to submaximal aerobic and maximal anaerobic exercise suggests differential activation mechanisms for PBK under these circumstances.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Muscle biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The muscle biopsy is usually normal or reveals subsarcolemmal accumulation of glycogen, primarily in type 2B fibers. The glycogen particles appear free and structurally normal by electron microscopy. Quantitation of muscle glycogen reveals either normal or slightly increased amounts. Immunohistochemical study of frozen muscle sections for phosphorylase is normal, and biochemical determination of PBK activity in muscle reveals either total absence or markedly decreased activity [
         <a href="#rid1">
          1
         </a>
         ]. However, the myopathic presentation is relatively mild, which has raised the question of whether this is a true disease or just a metabolic variant [
         <a href="#rid19">
          19,36
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no specific therapy for this disorder. Carbohydrate-rich feedings should be provided in patients with hypoglycemia, and increased protein intake (to 2 to 3 g/kg/day) is recommended by some experts [
         <a href="#rid37">
          37-39
         </a>
         ]. Nighttime cornstarch can be used as a slowly absorbed form of glucose. Patients should be monitored for progressive liver disease, particularly in the autosomal form.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Phosphorylase b kinase (PBK) converts phosphorylase b (less active) to phosphorylase a (more active) with a resulting increase in glycogenolysis. PBK also catalyzes the conversion of glycogen synthase from a more to a less active form. (See
         <a class="local">
          'Phosphorylase b kinase'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PBK deficiency is genetically heterogeneous, with both autosomal recessive and X-linked forms. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many cases of PBK deficiency are mild, but more severe disease can be seen. They typically present in early childhood with growth retardation and hepatomegaly, sometimes with hypoglycemia or inappropriate ketosis. The response to glucagon is normal. Symptoms generally resolve over time so that most adults are asymptomatic. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis is made by genetic testing or by reduced or absent PBK activity in the affected tissue, either liver or muscle, if molecular testing is negative. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no specific therapy for PBK deficiency. Carbohydrate-rich feedings and increased dietary protein should be provided in patients with hypoglycemia and/or ketosis. Patients should be monitored for progressive liver disease. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1994. p.1554.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones TA, da Cruz e Silva EF, Spurr NK, et al. Localisation of the gene encoding the catalytic gamma subunit of phosphorylase kinase to human chromosome bands 7p12-q21. Biochim Biophys Acta 1990; 1048:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Achouitar S, Goldstein JL, Mohamed M, et al. Common mutation in the PHKA2 gene with variable phenotype in patients with liver phosphorylase b kinase deficiency. Mol Genet Metab 2011; 104:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burwinkel B, Shin YS, Bakker HD, et al. Mutation hotspots in the PHKA2 gene in X-linked liver glycogenosis due to phosphorylase kinase deficiency with atypical activity in blood cells (XLG2). Hum Mol Genet 1996; 5:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burwinkel B, Maichele AJ, Aagenaes O, et al. Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase beta subunit (PHKB). Hum Mol Genet 1997; 6:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francke U, Darras BT, Zander NF, Kilimann MW. Assignment of human genes for phosphorylase kinase subunits alpha (PHKA) to Xq12-q13 and beta (PHKB) to 16q12-q13. Am J Hum Genet 1989; 45:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maichele AJ, Burwinkel B, Maire I, et al. Mutations in the testis/liver isoform of the phosphorylase kinase gamma subunit (PHKG2) cause autosomal liver glycogenosis in the gsd rat and in humans. Nat Genet 1996; 14:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burwinkel B, Rootwelt T, Kvittingen EA, et al. Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG2 gene. Pediatr Res 2003; 54:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kido J, Mitsubuchi H, Watanabe T, et al. A female patient with GSD IXc developing multiple and recurrent hepatocellular carcinoma: a case report and literature review. Hum Genome Var 2021; 8:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wehner M, Clemens PR, Engel AG, Kilimann MW. Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Hum Mol Genet 1994; 3:1983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bak H, Cordato D, Carey WF, Milder D. Adult-onset exercise intolerance due to phosphorylase b kinase deficiency. J Clin Neurosci 2001; 8:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echaniz-Laguna A, Akman HO, Mohr M, et al. Muscle phosphorylase b kinase deficiency revisited. Neuromuscul Disord 2010; 20:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nyegaard M, Overgaard MT, Søndergaard MT, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet 2012; 91:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crotti L, Johnson CN, Graf E, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 2013; 127:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crotti L, Spazzolini C, Tester DJ, et al. Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. Eur Heart J 2019; 40:2964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           İnci A, Kılıç Yıldırım G, Cengiz Ergin FB, et al. Expected or unexpected clinical findings in liver glycogen storage disease type IX: distinct clinical and molecular variability. J Pediatr Endocrinol Metab 2022; 35:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willems PJ, Gerver WJ, Berger R, Fernandes J. The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr 1990; 149:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schippers HM, Smit GP, Rake JP, Visser G. Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX). J Inherit Metab Dis 2003; 26:43.
          </a>
         </li>
         <li class="breakAll">
          Akman HO, Oldfors A, DiMauro S. Glycogen storage diseases of muscle. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach, Darras BT, Jones HRJ, Ryan MM, et al (Eds), Academic Press, San Diego 2015. p.735.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wuyts W, Reyniers E, Ceuterick C, et al. Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A 2005; 133A:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abarbanel JM, Bashan N, Potashnik R, et al. Adult muscle phosphorylase "b" kinase deficiency. Neurology 1986; 36:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van den Berg IE, Berger R. Phosphorylase b kinase deficiency in man: a review. J Inherit Metab Dis 1990; 13:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clemens PR, Yamamoto M, Engel AG. Adult phosphorylase b kinase deficiency. Ann Neurol 1990; 28:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servidei S, Metlay LA, Chodosh J, DiMauro S. Fatal infantile cardiopathy caused by phosphorylase b kinase deficiency. J Pediatr 1988; 113:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regalado JJ, Rodriguez MM, Ferrer PL. Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency. Pediatr Cardiol 1999; 20:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burwinkel B, Scott JW, Bührer C, et al. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet 2005; 76:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akman HO, Sampayo JN, Ross FA, et al. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase. Pediatr Res 2007; 62:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laforêt P, Richard P, Said MA, et al. A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis. Neuromuscul Disord 2006; 16:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bali DS, Goldstein JL, Fredrickson K, et al. Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene. Mol Genet Metab 2014; 111:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burwinkel B, Shiomi S, Al Zaben A, Kilimann MW. Liver glycogenosis due to phosphorylase kinase deficiency: PHKG2 gene structure and mutations associated with cirrhosis. Hum Mol Genet 1998; 7:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bührer C, van Landeghem F, Brück W, et al. Fetal-onset severe skeletal muscle glycogenosis associated with phosphorylase-b kinase deficiency. Neuropediatrics 2000; 31:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauchamp NJ, Dalton A, Ramaswami U, et al. Glycogen storage disease type IX: High variability in clinical phenotype. Mol Genet Metab 2007; 92:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kishnani PS, Goldstein J, Austin SL, et al. Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2019; 21:772.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ørngreen MC, Schelhaas HJ, Jeppesen TD, et al. Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology 2008; 70:1876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preisler N, Orngreen MC, Echaniz-Laguna A, et al. Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease? Neurology 2012; 78:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsilianidis LA, Fiske LM, Siegel S, et al. Aggressive therapy improves cirrhosis in glycogen storage disease type IX. Mol Genet Metab 2013; 109:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bali DS, Goldstein JL, Fredrickson K, et al. Clinical and Molecular Variability in Patients with PHKA2 Variants and Liver Phosphorylase b Kinase Deficiency. JIMD Rep 2017; 37:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross KM, Ferrecchia IA, Dahlberg KR, et al. Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies. Adv Nutr 2020; 11:439.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2908 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : DiMauro S, Tsujino S. Nonlysosomal glycogenoses. In: Myology, Engel A, Banker B (Eds), McGraw-Hill, New York 1994. p.1554.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2297530" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Localisation of the gene encoding the catalytic gamma subunit of phosphorylase kinase to human chromosome bands 7p12-q21.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21911307" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Common mutation in the PHKA2 gene with variable phenotype in patients with liver phosphorylase b kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8733134" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mutation hotspots in the PHKA2 gene in X-linked liver glycogenosis due to phosphorylase kinase deficiency with atypical activity in blood cells (XLG2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9215682" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase beta subunit (PHKB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2757032" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Assignment of human genes for phosphorylase kinase subunits alpha (PHKA) to Xq12-q13 and beta (PHKB) to 16q12-q13.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8896567" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Mutations in the testis/liver isoform of the phosphorylase kinase gamma subunit (PHKG2) cause autosomal liver glycogenosis in the gsd rat and in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12930917" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34876562" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A female patient with GSD IXc developing multiple and recurrent hepatocellular carcinoma: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7874115" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11386811" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Adult-onset exercise intolerance due to phosphorylase b kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20080404" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Muscle phosphorylase b kinase deficiency revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23040497" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23388215" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Calmodulin mutations associated with recurrent cardiac arrest in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31170290" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35038814" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Expected or unexpected clinical findings in liver glycogen storage disease type IX: distinct clinical and molecular variability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2303074" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12872839" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12872839" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15637709" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3083284" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Adult muscle phosphorylase "b" kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2122111" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phosphorylase b kinase deficiency in man: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2252364" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Adult phosphorylase b kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3385534" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Fatal infantile cardiopathy caused by phosphorylase b kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10368461" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Infantile hypertrophic cardiomyopathy of glycogenosis type IX: isolated cardiac phosphorylase kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15877279" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667862" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16487706" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A new mutation in PRKAG2 gene causing hypertrophic cardiomyopathy with conduction system disease and muscular glycogenosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673802" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Glycogen storage diseases presenting as hypertrophic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24389071" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9384616" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Liver glycogenosis due to phosphorylase kinase deficiency: PHKG2 gene structure and mutations associated with cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10832587" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Fetal-onset severe skeletal muscle glycogenosis associated with phosphorylase-b kinase deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17689125" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Glycogen storage disease type IX: High variability in clinical phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30659246" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Diagnosis and management of glycogen storage diseases type VI and IX: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18401027" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22238410" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Muscle phosphorylase kinase deficiency: a neutral metabolic variant or a disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23578772" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Aggressive therapy improves cirrhosis in glycogen storage disease type IX.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28283841" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical and Molecular Variability in Patients with PHKA2 Variants and Liver Phosphorylase b Kinase Deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665208" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
